Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain

Brain Research

Volumn 733, Issue 1, 1996, Pages 101-104

  Matsuura, Kouji ^a   Kabuto, Hideaki ^a   Makino, Hiroshi ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

6 Hydroxydopamine; Amine concentration; Cyclosporin A; Degeneration of nigrostriatal dopamine neurons; Dopamine turnover; Parkinson's disease

Indexed keywords

CYCLOSPORIN A; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 0030576848     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00686-5     Document Type: Article

References (24)

1. [1] Altar, C.A., Boylan, C.B., Fritsche, M., Jackson, C., Hyman, C. and Lindsay, R.M., The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra, Exp. Neurol., 130 (1994) 31-40.
2. [2] Altar, C.A., Boylan, C.B., Fritsche, M., Jones, B.E., Jackson, C., Wiegand, S.J., Lindsay, R.M. and Hyman, C., Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions, J. Neurochem., 63 (1994) 1021-1032.
3. [3] Altar, C.A., Boylan, C.B., Jackson, C., Hershenson, S., Miller, J., Wiegand, S., Lindsay, R.M. and Hyman, C., Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo, Proc. Natl. Acad. Sci. USA, 89 (1992) 11347-11351.
4. [4] Altar, C.A., Marien, M.R. and Marshall, J.F., Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury, J. Neurochem., 48 (1989) 390-399.
5. [5] Banati, R.B., Gehrmann, J., Schubert, P. and G.W., K., Cytotoxicity of microglia, Glia, 7 (1993) 111-118.
6. [6] Goto, S., Matsykado, Y., Mihara, Y., Inoue, N. and Miyamoto, E., The distribution of calcineurin in rat brain by light and electron microscopic immunohistochemistry and enzyme-immunoassay, Brain Res., 397 (1986) 161-172.
7. [7] Kitamura, Y., Itano, Y., Kubo, T. and Nomura, Y., Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice, J. Neuroimmunol., 50 (1994) 221-224.
8. [8] Kondo, Y., Ogawa, N., Asanuma, M., Nishibayashi, S., Iwata, E. and Mori, A., Cyclosporin A prevents ischemia-induced reduction of muscarinic acetylcholine receptors with suppression of microglial activation in gerbil hippocampus, Neurosci. Res., 22 (1995) 123-127.
9. [9] Lad, R.P., Smith, M.A. and Hilt, D.C., Molecular cloning and regional distribution of rat brain cyclophilin, Mol. Brain Res., 9 (1991) 239-244.
10. [10] Lindsay, R.M., Altar, C.A., Cedarbaum, J.M., Hyman, C. and Wiegand, S.J., The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease, Exp. Neurol., 124 (1993) 103-118.
11. [11] Martin-Iverson, M.T., Todd, K.G. and Altar, C.A., Brain-derived neurotrophic factor and neurotrophin-3 activates striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine, J. Neurosci., 14 (1994) 1262-1270.
12. [12] McGeer, P.L., Itagaki, S., Boyes, B.E. and McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38 (1988) 1285-1291.
13. [13] Mones, R.J., Elizan, T.S. and Siegel, G.J., Induced dyskinesia in 51 patients with Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 34 (1971) 668.
14. [14] Ogawa, N., Haba, K., Asanuma, M. and Mori, A., Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile, Brain Res., 556 (1991) 271-279.
15. [15] Ogawa, N., Tanaka, K., Kondo, Y., Asanuma, M., Mizukawa, K. and Mori, A., The preventive effect of cyclosporin A, an immunosuppressant, on theblate onset reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia, Neurosci. Lett., 152 (1993) 173-176.
16. [16] Shiga, Y., Onodera, H., Matsuo, Y. and Kogure, K., Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res., 595 (1992) 145-148.
17. [17] Shults, C.W., Matthews, R.T., Altar, C.A., Hill, L.R. and Langlais, P.J., A single intramesencephalic injection of brain-derived neurotrophic factor induces persistent rotational asymmetry in rats, Exp. Neurol., 125 (1994) 183-194.
18. [18] Slivka, A. and Cohen, G., Hydroxyl radical attack on dopamine, J. Biol. Chem., 15 (1985) 15466-15472.
19. [19] Spina, M.B., Squinto, S.P., Miller, J., Lindsay, R.M. and Hyman, C., Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system, J. Neurochem., 59 (1992) 99-106.
20. [20] Steiner, J.P., Dawson, T.M., Fotuhi, M., Glatt, C.E., Snowman, A.M., Cohen, N. and Synder, S.H., High brain densities of the immunophilin FKBP colocalized with calcineurin, Nature, 358 (1992) 584-587.
21. [21] Rinne, U.K., Sonnien, V. and Hyyppa, M., Effect of 1-dopa on brain monoamines and their metabolites in Parkinson's disease, Life Sci., 10 (1971) 549-557.
22. [22] Walaas, S.I., Aswad, D.W. and Greengard, P., A dopamine-and cyclic AMP-regulated phosphoprotein enriched in dopamine innervated brain regions, Nature, 301 (1983) 69-71.
23. [23] Wera, S. and Neyts, J., Calcineurin as a possible new target for treatment of Parkinson's disease, Med. Hypothes. 43 (1994) 132-134.
24. [24] Zigmond, M.J., Acheson, A.L., Stachowiak, M.K. and Stricker, E.M., Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism, Arch. Neurol., 41 (1984) 856-864.